logo
Plus   Neg
Share
Email

Danaher Guides Q3 Revenue Growth Above Estimates - Quick Facts

While reporting financial results for the second quarter on Thursday, medical company Danaher Corp. (DHR) said it anticipates adjusted core revenue growth for the third quarter, including Cytiva, to be in the mid- to high-single digit range.

On average, analysts polled by Thomson Reuters expect the company to report revenue growth of 4.0 percent to $5.24 billion or the quarter.

In early April, the company had withdrawn its financial guidance for the full year 2020, due to the evolving and uncertain impact of the coronavirus (COVID-19) pandemic.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT